According to Future Market Insights (FMI), the global human milk oligosaccharide (HMO) market is estimated to reach USD 100.8 million in 2024. Over the forecast period, human milk oligosaccharide sales are poised to increase at a CAGR of 6.5%. The global market is estimated to reach USD 161.6 million by 2034.
The growing demand for infant formula products that replicate the nutritional benefits of breast milk is driving the expansion of the human milk oligosaccharide (HMO) market. As awareness of the unique advantages of breast milk increases, parents and caregivers are increasingly seeking HMOs that closely mimic its composition to ensure optimal infant nutrition.
Factors such as rising birth rates, urbanization, and the increasing number of working mothers are contributing to a higher reliance on HMOs as a key source of infant nutrition. Moreover, advances in extraction and purification technologies are making HMOs more accessible to formula manufacturers and other industries aiming to incorporate them into their products.
Major companies are ramping up research and development efforts to create innovative HMO structures. They are also forming strategic partnerships with infant formula manufacturers while optimizing production processes for greater cost efficiency and scalability.
Key Takeaways from the Human Milk Oligosaccharide Market Report:
- The global human milk oligosaccharide market is estimated to be USD 100.8 million in 2024.
- The global market is expected to surge at a CAGR of 6.5% by 2034.
- Based on product type, the fucosylated segment is expected to reach a valuation of USD 42.9 million by 2034.
- During the forecast period, China is expected to rise at a CAGR of 5.5%.
- Demand for human milk oligosaccharides in Japan is anticipated to rise at a steady CAGR of 4.8% by 2034.
“The human milk oligosaccharide (HMO) market is experiencing robust growth fueled by rising awareness of their health benefits and expanding applications beyond infant nutrition. As demand continues to surge, innovations in production technologies and regulatory advancements are set to be pivotal in shaping the market’s trajectory and fostering further development.” -says Nandini Roy Choudhury (client Partner for Food and Beverages at Future Market Insights, Inc.)
Competitive Landscape
Jennewein Biotechnologies GmbH, KYOWA HAKKO BIO CO. LTD., DSM, Nestle Health Science, DUPONT, zuChem Inc., Glycosyn LLC, Elicityl SA, and Dextra Laboratories Limited are key human milk oligosaccharides manufacturers listed in the report.
The human milk oligosaccharide (HMO) market has a diverse and dynamic competitive landscape. Leading companies focus on research & development, new formulations, and sustainable sourcing to expand their customer base. Key manufacturers also emphasize product certifications, environmentally friendly practices, and satisfying the increased demand for natural & sustainable ingredients.
For instance,
- In 2021, BASF announced the approval of PREBILAC, its 2’-FL brand, by Australia’s Therapeutic Goods Administration (TGA).
- In 2022, Kyowa Hakko Bio Co. Ltd, a subsidiary of Kirin Holdings Company, Limited, finalized the construction of a manufacturing facility dedicated to the production of human milk oligosaccharides (HMOs) at its Thai subsidiary, Thai Kyowa Biotechnologies Co, Ltd.
Get More Valuable Insights
Future Market Insights (FMI), in its new offering, provides an unbiased analysis of the global human milk oligosaccharide market, presenting historical demand data (2019 to 2023) and forecast statistics for the period from 2024 to 2034.
The study incorporates compelling insights on the human milk oligosaccharide market based on product type (fucosylated [2FL, 2FL DFL, and 3FL], silylated [3SL and 6SL], and non-fucosylated neutral [LNT, LNnT, and LNFP], end-use (infant formula and dietary supplements), and regions.
Key Companies Profiled
- Jennewein Biotechnologie GmbH
- KYOWA HAKKO BIO CO. LTD.
- DSM
- Nestle Health Science
- DUPONT
- zuChem Inc.
- Glycosyn LLC
- Elicityl SA
- Dextra Laboratories Limited
- Carbosynth Limited
Key Coverage in the Global Human Milk Oligosaccharide Industry Research Report
- Adjacent Study on Human Milk Oligosaccharides Benefits and Nutritional Products Human Milk Oligosaccharides
- Detailed Market Analysis of Human Milk Oligosaccharides Supplement
- Ongoing Innovations in Human Milk Oligosaccharides Formula
- Growth Prospects for Baby Food Market in the United States
- Top Players in Baby Food and Infant Formula Market
- Human Milk Oligosaccharides and Immune System Development
Comprehensive Market Insights: Full Report Overview
Human Milk Oligosaccharide (HMO) Market Segmentation by Category
By Product Type:
- Fucosylated
- 2FL
- 2FL DFL
- 3FL
- Silylated
- 3SL
- 6SL
- Non-fucosylated Neutral
- LNT
- LNnT
- LNFP
By End-use:
- Infant Formula
- Dietary Supplements
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Middle East and Africa
- Oceania
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Join us as we commemorate 10 years of delivering trusted market insights. Reflecting on a decade of achievements, we continue to lead with integrity, innovation, and expertise.
Contact FMI:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
